Tella Pharma to Open Clinical Trial Manufacturing Facility in March
Located at the Development Center for Regenerative Medicine and Cell Therapy
Established by Kanagawa Prefecture

Tella Pharma, Inc., (location: Shinjuku-ku, Tokyo, representative: Junichi Miyazawa) a consolidated subsidiary of tella, inc., has established a facility for the production of clinical trial products for physician-led clinical trial concerning the dendritic cell (DC) vaccine TLP0-001. This clinical trial is conducted by Wakayama Medical University. The production base is located at the Life Innovation Center in the city of Kawasaki in Kanagawa prefecture.

The most innovative aspect of the new facility is the extensive use of robots, automation and the Internet of things. Operating this production base will lower the cost of making cell products and dramatically increase the output volume per floor area. The company plans to produce DC vaccines at this facility.

The Life Innovation Center was established by the Kanagawa prefectural government as a location for transforming technologies involving regenerative medicine and cell therapy into practical use. With the objective of creating the facility as a source of global innovation Kanagawa prefecture is working closely with the Japanese government, industry associations and overseas organizations. Many companies performing R&D in the fields of regenerative medicine and cell therapy are setting up operations at the center. This creates an ideal environment for the production of clinical trial products and the development of regenerative medicine and other products of Tella Pharma.

Easy access to land and air transport is one more advantage of the Life Innovation Center. As the TLP0-001 expands to the stage where tests are performed at medical institutions throughout Japan, this location will allow the establishment of a production and distribution framework for clinical trial products that serves all areas of the country.

Tella Pharma is committed to making the DC vaccine available as soon as possible to people who can benefit from this technology. The company’s goal is to receive regulatory approval in 2022.
【Profile of the Kanagawa Production Facility】
・Name Tella Pharma Tonomachi Cell Culture Base (tentative)
・Location Life Innovation Center, 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa
・Products DC cell vaccine and other products
・Output 185 specimen cultures/month
・Start of operation Operations to begin in March 2017 (planned)

【Drawing of the completed building】

(Reference) Video of the production facility: https://youtu.be/IeFgSQpZi1M
Outline of Life Innovation Center: http://www.pref.kanagawa.jp/cnt/f531405/p1044967.html